After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).
It’s the first FDA approval for a pain medication in 25 years. How does the drug work, and who is it for?
A newly approved pain medication, suzetrigine, is the first nonopioid analgesic in 25 years to receive clearance from the U.S ...
El Mundo on MSN3d
US approves a new painkiller with less risk of addiction than opioids and equally potentThe suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...
Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...
A modern control scheme and HD textures clash awkwardly with the boxy old levels of Lara's past, in three of her least ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is ...
For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback